Compare Enveric Biosciences Inc (ENVB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs IDEXX Laboratories, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5945.6× Enveric Biosciences Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 64,867). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| ENVB | IDXX | |
|---|---|---|
Market Cap | $6.80M | $40.43B |
Volume | 64,867 | 692,164 |
Sector | Health | Health |
52-Week High | $10.80 | $766.68 |
52-Week Low | $1.27 | $504.70 |
Typical Hold Time | 14 Days | 46 Days |
Enterprise Value | -$1.49M | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.52, up 1.67% with a bearish technical outlook despite recent earnings beats. The company shows no revenue but has improved quarterly EPS performance, with Q4 2025 turning positive. Analyst sentiment is bullish with 75% buy ratings, while technical indicators show selling pressure with 15 sell signals versus 1 buy.
Investment outlook remains speculative given negative profitability metrics and zero revenue, though patent developments and FDA guidance provide potential catalysts. Key risks include cash burn and clinical trial outcomes, while institutional support through financing offers near-term stability.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding the $3.94 estimate. Revenue grew to $4.3 billion in 2025, and net income margin expanded to 25.03%. Recent acquisitions like CoVetAI aim to enhance veterinary workflow intelligence.
The outlook remains positive given robust profitability and analyst consensus, but risks include foreign exchange headwinds and competitive pressures. With a consensus price target of $665, representing ~30% upside, the stock offers growth potential for investors comfortable with its premium valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
